L'accès aux droits sociaux dans les situations d'accueil (la mise en jeu de la personne)

RENNES2-BU Centrale (352382101) / SudocSudocFranceF

Human Papillomavirus Types Distribution in Organised Cervical Cancer Screening in France

International audienceBackground: Knowledge of prevalence rates and distribution of human papillomavirus (HPV) genotypes prior high HPV vaccine coverage is necessary to assess its expected impact on HPV ecology and on cervical lesions and cancers.Methods: Residual specimens of cervical cytology (N = 6,538) were obtained from 16 sites participating in organised cervical cancer screening pilot programs throughout France, anonymised and tested for HPV DNA using the PapilloCheck® genotyping test. Samples were stratified according to age of women and cytological grades.Results: The age-standardised prevalence rates of HPV 16 and/or 18 (with or without other high-risk types) was 47.2% (95% Confidence Interval, CI: 42.4–52.1) in high-grade squamous intraepithelial lesions (HSILs), 20.2% in low-grade SIL (95% CI: 16.7–23.7) and 3.9% (95% CI: 2.8–5.1) in normal cytology. Overall HR HPV were detected in 13.7% (95%I CI: 11.7–15.6) of normal cytology. In women below 30 years of age, 64% of HSILs were associated with HPV16 and/or 18. In our study population, HPV16 was the most commonly detected type in all cervical grades with prevalence rates ranking from 3.0% in normal cytology to 50.9% in HSILs. HPV16 was also detected in 54% (27/50) of invasive cervical cancers including 5 adenocarcinomas.Conclusion: HPV16 was strongly associated with cervical precancer and cancer. The high prevalence rates of HPV16/18 infection among women below 30 years of age with HSILs suggests that the impact of vaccination would be primarily observed among young women

Human papillomavirus types by cytology grades (n = 6139).

<p>HPV types were detected with the PapilloCheck® technique. N+: Number of positive samples. ASC-US, Atypical Squamous Cells of Undetermined Significance; LSIL, Low grade Squamous Intra-epithelial Lesion; HSIL, High grade Squamous Intra-epithelial Lesion; tot, total.</p

Geographic location of participants and cytology grade of samples.

<p>HR HPV, High Risk HPV; ASC-US, Atypical Squamous Cells of Undetermined significance; LSIL, Low grade Squamous Intra-epithelial Lesion; HSIL, High grade Squamous Intra-epithelial Lesion.</p

Sample Submission and Human Papilloma Virus (HPV) Testing Algorithm for Residual Liquid Based Cytology (LBC) Samples.

<p>Sample Submission and Human Papilloma Virus (HPV) Testing Algorithm for Residual Liquid Based Cytology (LBC) Samples.</p

Age standardized infection rate by cytology grade.

<p>HR HPV, High Risk HPV; ASC-US, Atypical Squamous Cells of Undetermined Significance; LSIL, Low grade Squamous Intra-epithelial Lesion; HSIL, High grade Squamous Intra-epithelial Lesion; CI, Confidence Interval.</p

Age specific prevalence of HPV infection in different cytology groups.

<p>Prevalence of HPV infection High Risk (HR) but not 16 and/or 18 and HPV16 and/or 18 without or with another HPV type by cervical grade and age group. ASC-US, Atypical Squamous Cells of Undetermined Significance; LSIL, Low Grade Squamous Intra-epithelial Lesion; HSIL, High Grade Squamous Intra-epithelial Lesion.</p

Prevalence of HR HPV by age group among the 5326 women eligible for routine screening (age 25–65).

<p>HR HPV, High Risk HPV; CI, Confidence Interval.</p

Seroepidemiology of the Seasonal Human Coronaviruses NL63, 229E, OC43 and HKU1 in France

International audienceBackground. The seasonal human coronaviruses (HCoV) NL63, 229E, OC43, and HKU1 are globally endemic, yet the majority of HCoV infections remain undiagnosed. Methods. In a cross-sectional study, 2389 serum samples were collected from children and adults in France in 2020. In a longitudinal cohort study, 2520 samples were collected from 898 French individuals followed up between 2020 and 2021. Antibodies to HCoVs were measured using a bead-based multiplex assay. Results. The rate of waning of anti-HCoV spike immunoglobulin G antibodies was estimated as 0.22-0.47 year −1 for children, and 0.13-0.27 year −1 for adults. Seroreversion was estimated as 0.31-1.37 year −1 in children and 0.19-0.72 year −1 in adults. The estimated seroconversion rate in children was consistent with 20%-39% of children being infected every year with each HCoV. Conclusions. The high force of infection in children indicates that HCoVs may be responsible for a substantial proportion of fever episodes experienced by children

Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients.

BACKGROUND: Myeloproliferative disorders are characterized by clonal expansion of normal mature blood cells. Acquired mutations giving rise to constitutive activation of the JAK2 tyrosine kinase has been shown to be present in the majority of patients. Since the demonstration that the V617F mutation in the exon 14 of the JAK2 gene is present in about 90% of patients with Polycythemia Vera (PV), the detection of this mutation has become a key tool for the diagnosis of these patients. More recently, additional mutations in the exon 12 of the JAK2 gene have been described in 5 to 10% of the patients with erythrocytosis. According to the updated WHO criteria the presence of these mutations should be looked for in PV patients with no JAK2 V617F mutation. Reliable and accurate methods dedicated to the detection of these highly variable mutations are therefore necessary. METHODS/FINDINGS: For these reasons we have defined the conditions of a High Resolution DNA Melting curve analysis (HRM) method able to detect JAK2 exon 12 mutations. After having validated that the method was able to detect mutated patients, we have verified that it gave reproducible results in repeated experiments, on DNA extracted from either total blood or purified granulocytes. This HRM assay was further validated using 8 samples bearing different mutant sequences in 4 different laboratories, on 3 different instruments. CONCLUSION: The assay we have developed is thus a valid method, adapted to routine detection of JAK2 exon 12 mutations with highly reproducible results